NEO vs LH vs DGX vs SLNO

For growth investors, Quest Diagnostics Incorporated (DGX) is the stronger pick with 11.

8% revenue growth year-over-year, versus 7. 2% for Labcorp Holdings Inc. (LH). Quest Diagnostics Incorporated (DGX) offers the better valuation at 23. 2x trailing P/E (18. 9x forward), making it the more compelling value choice. Analysts rate NeoGenomics, Inc. (NEO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Quest Diagnostics Incorporated (DGX) is the cheapest at 23.

2x versus Soleno Therapeutics, Inc. at 135. 9x. On forward P/E, Soleno Therapeutics, Inc. is actually cheaper at 13. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +69.

8%, compared to -74. 4% for NeoGenomics, Inc. (NEO). Over 10 years, the gap is even starker: DGX returned +197. 5% versus SLNO's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quest Diagnostics Incorporated (DGX) is the lower-risk stock at -0.

06β versus NeoGenomics, Inc. 's 1. 37β — meaning NEO is approximately -2423% more volatile than DGX relative to the S&P 500. On balance sheet safety, Soleno Therapeutics, Inc. (SLNO) carries a lower debt/equity ratio of 1% versus 95% for Quest Diagnostics Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Quest Diagnostics Incorporated (DGX) is pulling ahead at 11.

8% versus 7. 2% for Labcorp Holdings Inc. (LH). On earnings-per-share growth, the picture is similar: Soleno Therapeutics, Inc. grew EPS 108. 9% year-over-year, compared to -35. 5% for NeoGenomics, Inc.. Over a 3-year CAGR, NEO leads at 12. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Soleno Therapeutics, Inc.

(SLNO) is the more profitable company, earning 11. 0% net margin versus -14. 9% for NeoGenomics, Inc. — meaning it keeps 11. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DGX leads at 14. 5% versus -9. 1% for NEO. At the gross margin level — before operating expenses — SLNO leads at 98. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Soleno Therapeutics, Inc.

(SLNO) trades at 13. 9x forward P/E versus 61. 9x for NeoGenomics, Inc. — 48. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NEO: 70. 4% to $19. 00.

In this comparison, DGX (1.

5% yield), LH (1. 1% yield) pay a dividend. NEO, SLNO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Quest Diagnostics Incorporated (DGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

06), 1. 5% yield, +197. 5% 10Y return). Both have compounded well over 10 years (DGX: +197. 5%, NEO: +42. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

LH, DGX pay a dividend while NEO, SLNO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.